[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100523298":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":26,"responsibleParty":50,"collaborators":52,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"National Institutes of Health Clinical Center (CC)","NIH",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"allogeneic HSCT",null,"Up to 30 men or women, 18 - 70 years of age, who are being treated with allogeneic HSCT for a hematologic malignancy, blood, or immune system disorder at the NIH Clinical CenterUp to 10 children 5 - 17 years of age who are being treated with allogeneic HSCT for a hematologic malignancies, blood, or immune system disorder at the NIH Clinical CenterNIH Clinical Center",[13],{"name":14,"affiliation":15,"role":16},"Anthony F Suffredini, M.D.","National Heart, Lung, and Blood Institute (NHLBI)","PRINCIPAL_INVESTIGATOR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Gloria Y Pastor, C.R.N.P.","CONTACT","(301) 402-3484","pastorg@cc.nih.gov",{"name":14,"role":20,"phone":24,"phoneExt":10,"email":25},"(301) 496-9320","asuffredini@mail.nih.gov",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"National Institutes of Health Clinical Center","RECRUITING","Bethesda","Maryland","20892","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-77.10026,38.98067,{"lat":39,"lon":38},[42,47],{"name":43,"role":20,"phone":44,"phoneExt":45,"email":46},"NIH Clinical Center Office of Patient Recruitment (OPR)","800-411-1222","TTY dial 711","ccopr@nih.gov",{"name":48,"role":20,"phone":21,"phoneExt":10,"email":49},"Gloria Pastor","gloria.pastor@nih.gov",{"type":51,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[53],{"name":5,"class":6},"100523298","early-detection-of-infectious-and-noninfectious-lung-diseases-following-allogeneic-hematopoietic-stem-cell-transplantation-100523298",false,"NCT06093867","Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation","A Prospective Approach for the Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Stated willingness to comply with all study procedures and availability for the duration of the study.\n2. Male or female, aged 5 - 70 years of age\n3. Are to be treated with allogeneic HSCT for a hematologic malignancy, blood, or immune system disorders at the NIH Clinical Center.\n4. Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1\\. Pregnancy or lactation\n\na. HSCT is not available to pregnant women or lactating women in the intramural program. For women of reproductive potential, have a negative serum pregnancy test during the screening period. Women of reproductive potential are defined as sexually mature women who have not undergone a hysterectomy, bilateral oophorectomy, or tubal occlusion; or who have not been naturally postmenopausal (i.e., who have not menstruated at all for at least the preceding 1 year prior to signing informed consent unrelated to hormonal contraception).","ALL","5 Years","70 Years",{"count":65,"type":66},40,"ESTIMATED","OBSERVATIONAL","Background:\n\nStem cell transplants (called hematopoietic stem cell transplantation, or HSCT) are used to treat various diseases. But when the cells for this procedure are donated by someone other than the person who receives the HSCT ( allogeneic HSCT ), the recipient has an increased risk of lung inflammation and scarring. This happens when their immune cells attack healthy lung cells. In this natural history study, researchers will look for the best ways to detect developing lung inflammations earlier after an HSCT.\n\nObjective:\n\nTo see if certain tests can detect early signs of lung inflammation in people after HSCT.\n\nEligibility:\n\nPeople aged 5 to 70 years who will have HSCT as part of another NIH study.\n\nDesign:\n\nParticipants will undergo these tests prior to their HSCT. These tests will then be repeated regularly for 2 years:\n\nUltra-low dose computed tomography (CT) scans. Participants will lie on a table that slides through a machine; the machine uses X-rays to get pictures of the inside of the body. This type of scan uses less radiation than normal CT scans.\n\nBronchoscopy with lavage: Participants will be sedated. A flexible tube will be inserted through the mouth and into the airways. Salt water will be squirted into the lung, then sucked out to collect cells and fluids from the lung. Another tube with a camera may be inserted into the airways to take pictures.\n\nBlood tests. Blood will be drawn every 2 to 4 weeks.\n\nPulmonary function tests. Participants will breathe into a machine to test their lung function. They will see how far they can walk in 6 minutes.",[70],"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)",[72,73],"allogeneic hematopoietic stem cell transplantation (HSCT)","early detection of inflammatory injury","2026-06-18",{"date":76,"type":77},"2026-06-22","ACTUAL",{"date":79,"type":77},"2024-04-08",{"date":81,"type":66},"2029-10-01",{"name":15,"class":6},1]